Sorafenib inhibits the activity of both electron transport chain and ATP synthase to activate the PINK1, which is likely to be a general phenomenon.[18] These findings are striking, as Sorafenib was able to temporarily inhibit osteosarcoma progression,[17, 28] and Regorafenib was effective against recurrent and metastasis osteosarcoma.[17b,c] We propose that Sorafenib and Regorafenib may benefit cancer patients who are positive for the RAB22A‐NeoF1 fusion gene. This evidence concerns the gene RAB22A and cancer.